Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | RAB9A | P51151 | 5/20 | 0.71 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.61 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18528795 | 0.88 | NPC1 (0.69) | KDM4ENPC1RAB9ANOTUMHSD17B10 | |
| SCHEMBL417379 | 0.83 | NPC1 (1.00) | KDM4ENPC1RAB9ANOTUMDGAT1 | |
| SCHEMBL25184601 | 0.81 | NPC1 (0.57) | KDM4ENPC1RAB9ANOTUMDGAT1 | |
| SCHEMBL31043550 | 0.81 | NPC1 (0.57) | KDM4ENPC1RAB9ANOTUMDGAT1 | |
| SCHEMBL22116712 | 0.81 | NPC1 (0.57) | KDM4ENPC1RAB9ANOTUMHSD17B10 | |
| SCHEMBL29121393 | 0.81 | NPC1 (0.71) | KDM4ENPC1RAB9ANOTUMHSD17B10 | |
| SCHEMBL20767009 | 0.80 | NPC1 (0.72) | KDM4ENPC1RAB9ANOTUMDGAT1 | |
| SCHEMBL26673871 | 0.79 | NPC1 (0.78) | KDM4ENPC1RAB9ANOTUMDGAT1 | |
| SCHEMBL21777008 | 0.79 | KDM4E (0.62) | KDM4ENPC1RAB9ANOTUMHSD17B10 | |
| SCHEMBL18528796 | 0.79 | NPC1 (0.69) | KDM4ENPC1RAB9ANOTUMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025090727-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4531838-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | Kuda Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023234970-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA Therapeutics, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11447482-B1 | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis | KUDA Therapeutics, Inc. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | KUDA Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | KUDA Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| EP-2760856-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2760856-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2760856-A1 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| EP-0915856-A4 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-12 | — | — | EP | disclosed |
| CN-1116287-C | Diphenyl heterocycles as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 2003-07-30 | — | — | CN | disclosed |
| US-6271249-B1 | Diphenyl imidazoles as potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2001-08-07 | — | — | US | disclosed |
| US-6077861-A | MODULATORS OF THE LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM (BK) CHANNELS, THEREFORE, USEFUL IN THE TREATMENT OF ISCHEMIC STROKE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| CN-1226803-A | Diphenyl heterocycles as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 1999-08-25 | — | — | CN | disclosed |
| EP-0915856-A1 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Bristol-Myers Squibb Company (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5869509-A | TREAT DISORDERS RESPONSIVE TO OPENERS OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998004135-A1 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085138-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | KDM4E 4007/4885NPC1 1248/4885RAB9A 3432/4885 |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | HIF1AN, HIF1A, EGLN2 | KDM4E 1020/4885NPC1 1895/4885RAB9A 3536/4885 |
| US-11447482-B1 | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis | HIF1AN, HIF1A, EGLN2 | KDM4E 686/4885NPC1 2512/4885RAB9A 3136/4885 |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | HIF1AN, HIF1A, EGLN2 | KDM4E 686/4885NPC1 2512/4885RAB9A 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.